Durvalumab after chemoradiotherapy in stage III non-small cell lung cancer

被引：16
|
作者：
Tomasini, Pascale [1 ,2 ]
Greillier, Laurent [1 ,2 ]
Boyer, Arnaud [1 ,2 ]
Jeanson, Arnaud [1 ,2 ]
Barlesi, Fabrice [1 ,2 ]
机构：
[1] Aix Marseille Univ, Multidisciplinary Oncol & Therapeut Innovat Dept, AP HM, Marseille, France
[2] Aix Marseille Univ UM105, Inserm UMR1068, CNRS UMR7258, Predict Oncol Lab,Ctr Rech Cancerol Marseille, Marseille, France
来源：
JOURNAL OF THORACIC DISEASE | 2018年 / 10卷
关键词：
TREMELIMUMAB COMBINATION THERAPY; PLATINUM-BASED CHEMOTHERAPY; 1ST-LINE TREATMENT; PLUS TREMELIMUMAB; PATIENTS PTS; MEDI4736; PHASE-3; NSCLC; RADIOTHERAPY; MULTICENTER;
D O I：
10.21037/jtd.2018.04.61
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页码：S1032 / S1036
页数：5
相关论文
共 50 条
  • [31] DURVALUMAB-INDUCED IGA NEPHROPATHY IN STAGE III NON-SMALL CELL LUNG CANCER AFTER CHEMORADIATION
    Janagam, Pragna
    CHEST, 2021, 160 (04) : 1578A - 1578A
  • [32] COST-EFFECTIVENESS OF DURVALUMAB AFTER CHEMORADIATION IN STAGE III NON-SMALL CELL LUNG CANCER (NSCLC)
    Criss, S. D.
    Mooradian, M. J.
    Lumish, M. A.
    Reynolds, K. L.
    Kong, C. Y.
    VALUE IN HEALTH, 2018, 21 : S12 - S12
  • [33] Durvalumab Induces Sustained Survival Benefit After Concurrent Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
    Pujol, Jean-Louis
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (12) : 1271 - +
  • [34] Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Stage III Non-Small-Cell Lung Cancer (PACIFIC)
    Socinski, Mark A.
    Ozguroglu, Mustafa
    Villegas, Augusto
    Daniel, Davey
    Vicente, David
    Murakami, Shuji
    Hui, Rina
    Gray, Jhanelle E.
    Park, Keunchil
    Vincent, Mark
    Mann, Helen
    Newton, Michael
    Dennis, Phillip A.
    Antonia, Scott J.
    CLINICAL LUNG CANCER, 2021, 22 (06) : 549 - 561
  • [35] Concurrent chemoradiotherapy for elderly patients with stage III non-small cell lung cancer
    Kang, Ki Mun
    Jeong, Bae Kwon
    Ha, In Bong
    Chai, Gyu Young
    Lee, Gyeong Won
    Kim, Hoon Gu
    Kang, Jung Hoon
    Lee, Won Seob
    Kang, Myoung Hee
    RADIATION ONCOLOGY JOURNAL, 2012, 30 (03): : 140 - 145
  • [36] Induction chemotherapy versus chemoradiotherapy for stage III non-small cell lung cancer
    Higgins, K. A.
    Clough, R.
    Marks, L.
    Kelsey, C.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 72 (01): : S59 - S60
  • [37] Association of immune-related adverse events with durvalumab efficacy after chemoradiotherapy in patients with unresectable Stage III non-small cell lung cancer
    Haratani, Koji
    Nakamura, Atsushi
    Mamesaya, Nobuaki
    Sawa, Kenji
    Shiraishi, Yoshimasa
    Saito, Ryota
    Tanizaki, Junko
    Tamura, Yosuke
    Hata, Akito
    Tsuruno, Kosuke
    Sakamoto, Tomohiro
    Teraoka, Shunsuke
    Oki, Masahide
    Watanabe, Hiroshi
    Tokito, Takaaki
    Nagata, Kenji
    Masuda, Takeshi
    Nakamura, Yasushi
    Sakai, Kazuko
    Chiba, Yasutaka
    Ito, Akihiko
    Nishio, Kazuto
    Yamamoto, Nobuyuki
    Nakagawa, Kazuhiko
    Hayashi, Hidetoshi
    BRITISH JOURNAL OF CANCER, 2024, 130 (11) : 1783 - 1794
  • [38] Durvalumab in Stage III Non-Small-Cell Lung Cancer
    Copur, Mehmet S.
    Gauchan, Dron
    Ramaekers, Ryan
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (09): : 868 - 868
  • [39] Patterns and Incidence of Pneumonitis and Initial Treatment Outcomes with Durvalumab Consolidation Therapy after Radical Chemoradiotherapy for Stage III Non-Small Cell Lung Cancer
    Sato, Mizuki
    Odagiri, Kazumasa
    Tabuchi, Yuya
    Okamoto, Hiroaki
    Shimokawa, Tsuneo
    Nakamura, Yukiko
    Hata, Masaharu
    CANCERS, 2024, 16 (06)
  • [40] Outcomes of Chemoradiotherapy for Stage III Non-Small Cell Lung Cancer in South of Brazil
    Coelho, Juliano Ce
    Branco, Mariane Araujo
    Pirolli, Rafaela
    Muller, Carolina Beatriz
    Carissimi Schmidt, Luis Felipe
    Klamt, Fabio
    Geib, Guilherme
    Schwartsmann, Gilberto
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S684 - S684
12345